Terms: = Breast cancer AND MNX1, HB9, 3110, ENSG00000130675, P50219, HLXB9 AND Diagnosis
3 results:
1. Gene expression signatures of individual ductal carcinoma in situ lesions identify processes and biomarkers associated with progression towards invasive ductal carcinoma.
Rebbeck CA; Xian J; Bornelöv S; Geradts J; Hobeika A; Geiger H; Alvarez JF; Rozhkova E; Nicholls A; Robine N; Lyerly HK; Hannon GJ
Nat Commun; 2022 Jun; 13(1):3399. PubMed ID: 35697697
[TBL] [Abstract] [Full Text] [Related]
2. Diagnostic and therapeutic ERβ, HER2, BRCA biomakers in the histological subtypes of lung adenocarcinoma according to the IASLC/ATS/ERS classification.
Zhong L; Zhang C; Jia W; Zhang P
Ann Diagn Pathol; 2021 Apr; 51():151700. PubMed ID: 33465722
[TBL] [Abstract] [Full Text] [Related]
3. [Values of Minimal Apparent Diffusion Coefficient,Difference between Ratios of Apparent Diffusion Coefficients,and Dynamic Contrast-enhanced Magnetic Resonance Imaging Features in Diagnosing breast Ductal Carcinoma In Situ with Microinvasion].
Wu P; Cui L; Guo BH; Wang YC; Cui JS
Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2019 Dec; 41(6):737-745. PubMed ID: 31907122
[No Abstract] [Full Text] [Related]
